NEW YORK --

NYSE Euronext

(NYX)

, the operator of the New York Stock Exchange, is in talks to sell itself to rival

IntercontinentalExchange

(ICE) - Get Intercontinental Exchange, Inc. (ICE) Report

, according to reports.

People close to the discussions told

The Wall Street Journal

an announcement could come as early as Thursday.

Under a deal, ICE would value NYSE at $33 a share, a 37% premium to its closing price on Wednesday, according to a report from

CNBC

.

NYSE closed Wednesday at $24.05 and soared more than 20% in after-hours trading.

Bed Bath & Beyond

(BBBY) - Get Bed Bath & Beyond Inc. Report

on Wednesday issued forecasts for the fourth quarter and fiscal year that were below analysts' views.

The retailer said it expects fourth-quarter earnings of $1.60 to $1.67 a share, and fiscal-year earnings of $4.48 to $4.54 a share.

Analysts are calling for fourth-quarter earnings of $1.75 a share, and 2012 earnings of $4.62 a share.

Bed Bath & Beyond's board also authorized a new $2.5 billion stock buyback program.

5 Retail Sector Bargains to Buy Before 2013

Jabil Circuit

(JBL) - Get Jabil Inc. Report

posted fiscal first-quarter earnings on Wednesday that topped Wall Street estimates.

Adjusted earnings for the first quarter were 61 cents a share; analysts forecast profit of 56 cents a share.

Jabil said sales in the quarter rose to $4.64 billion from $4.33 billion a year earlier. Analysts were expecting sales of $4.41 billion.

TheStreet Recommends

Stephen Gillett Leaves Sinking-Ship Best Buy for Symantec

Research In Motion

( RIMM), the BlackBerry maker, is expected by analysts on Thursday to post a fiscal third-quarter loss of 35 cents a share.

RIM, which has steadily been losing market share in the U.S., is banking on reversing its fortunes with BlackBerry 10, the new operating system that will be unveiled at the end of next month.

An experimental therapy from

Amicus Therapeutics

(FOLD) - Get Amicus Therapeutics, Inc. Report

and

GlaxoSmithKline

(GSK) - Get GlaxoSmithKline plc Sponsored ADR Report

failed to improve kidney response in Fabry disease patients compared to placebo in a late-stage study, the companies disclosed late Wednesday.

Amicus shares closed Wednesday at $5.77 but fell 55% to $2.60 in after-hours trading.

Amicus Fabry Drug Fails Pivotal Trial

Analysts expect

ConAgra Foods

(CAG) - Get Conagra Brands, Inc. Report

on Thursday to report fiscal second-quarter earnings of 55 cents a share on revenue of $3.69 billion.

Discover Financial Services

(DFS) - Get Discover Financial Services Report

is expected by Wall Street to post fourth-quarter earnings Thursday of $1.11 a share.

-- Written by Joseph Woelfel

>To contact the writer of this article, click here:

Joseph Woelfel

>To submit a news tip, send an email to:

tips@thestreet.com

.